Gene Therapy Market by Type (Gene silencing), Vector (Viral (Retroviral, AAV), Non-viral (Oligonucleotide)), Gene Type (Receptors, Cytokine), Therapeutic Area (Oncology, Neurology), Delivery Method (In-Vivo, Ex-Vivo), RoA (IV) - Global Forecast to 2032

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SEGMENTATION
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY RESEARCH
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY RESEARCH
    • 2.1.2.1 Insights of primary experts
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 GLOBAL MARKET ESTIMATION
  • 2.2.2 SEGMENTAL MARKET SIZE ESTIMATION
• 2.3 MARKET GROWTH RATE PROJECTIONS
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 GENE THERAPY MARKET OVERVIEW
• 4.2 NORTH AMERICA: GENE THERAPY MARKET, BY THERAPY TYPE & COUNTRY (2024)
• 4.3 GENE THERAPY MARKET SHARE, BY END USER, 2024 VS 2032
• 4.4 GENE THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing demand for curative therapies for genetic disorders, rare diseases, and cancers
    • 5.2.1.2 Increasing investments in gene therapy research
    • 5.2.1.3 Technological advancements
    • 5.2.1.4 Robust clinical trial pipeline for gene therapy
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of gene therapy products
    • 5.2.2.2 Complex regulatory frameworks and ethical concerns regarding genetic modifications
    • 5.2.2.3 Limited manufacturing scalability
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Expansion into rare diseases and unmet needs
    • 5.2.3.2 Increasing focus on precision medicine
    • 5.2.3.3 Advancements in gene therapy delivery technologies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Complex commercial manufacturing and scaling process
    • 5.2.4.2 Short shelf life and supply chain challenges
    • 5.2.4.3 Lack of reimbursement
• 5.3 TECHNOLOGY ANALYSIS
  • 5.3.1 KEY TECHNOLOGIES
    • 5.3.1.1 CRISPR-Cas9
    • 5.3.1.2 RNA interference
    • 5.3.1.3 Viral vectors
  • 5.3.2 COMPLEMENTARY TECHNOLOGIES
    • 5.3.2.1 Stem cell therapy
    • 5.3.2.2 Omics technologies
  • 5.3.3 ADJACENT TECHNOLOGIES
    • 5.3.3.1 Nanoparticles
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 SUPPLY CHAIN ANALYSIS
  • 5.5.1 PROMINENT COMPANIES
  • 5.5.2 SMALL AND MEDIUM-SIZED ENTERPRISES
  • 5.5.3 END USERS
  • 5.5.4 INVESTORS, VENTURE CAPITALISTS, AND FUNDING BODIES
  • 5.5.5 REGULATORY BODIES
• 5.6 ECOSYSTEM ANALYSIS
• 5.7 PATENT ANALYSIS
• 5.8 PIPELINE ANALYSIS
• 5.9 REGULATORY LANDSCAPE
  • 5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION
  • 5.9.2 REGULATORY FRAMEWORK
  • 5.9.3 REIMBURSEMENT SCENARIO
• 5.10 PRICING ANALYSIS
  • 5.10.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
  • 5.10.2 AVERAGE SELLING PRICE TREND, BY REGION
• 5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.12 KEY CONFERENCES & EVENTS, 2025-2026
• 5.13 PORTER'S FIVE FORCES ANALYSIS
  • 5.13.1 THREAT OF NEW ENTRANTS
  • 5.13.2 THREAT OF SUBSTITUTES
  • 5.13.3 BARGAINING POWER OF SUPPLIERS
  • 5.13.4 BARGAINING POWER OF BUYERS
  • 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 BUYING CRITERIA
• 5.15 INVESTMENT & FUNDING SCENARIO
• 5.16 IMPACT OF AI ON GENE THERAPY MARKET

6 GENE THERAPY MARKET, BY THERAPY TYPE

• 6.1 INTRODUCTION
• 6.2 GENE SILENCING THERAPY
  • 6.2.1 FLEXIBILITY AND PRECISION OF GENE SILENCING THERAPIES TO SUPPORT GROWTH
• 6.3 CELL REPLACEMENT THERAPY
  • 6.3.1 LONG-TERM EFFECT OF THERAPY TO SUPPORT GROWTH IN ADOPTION
• 6.4 GENE AUGMENTATION THERAPY
  • 6.4.1 EFFECTIVENESS AGAINST MONOGENIC DISORDERS TO DRIVE MARKET
• 6.5 OTHER THERAPIES

7 GENE THERAPY MARKET, BY VECTOR

• 7.1 INTRODUCTION
• 7.2 VIRAL VECTORS
  • 7.2.1 RETROVIRAL VECTORS
    • 7.2.1.1 Advantages of retroviral vectors to support market growth
    • 7.2.1.2 Gamma-retroviral vectors
      • 7.2.1.2.1 Availability of gamma-retroviral vectors to support market growth
    • 7.2.1.3 Lentiviral vectors
      • 7.2.1.3.1 North America to dominate lentiviral vectors market
  • 7.2.2 AAV VECTORS
    • 7.2.2.1 Focus of clinical pipeline on adeno-associated viral vectors to drive growth
  • 7.2.3 OTHER VIRAL VECTORS
• 7.3 NON-VIRAL VECTORS
  • 7.3.1 OLIGONUCLEOTIDE VECTORS
    • 7.3.1.1 Oligonucleotides to account for largest share of non-viral vectors market
  • 7.3.2 OTHER NON-VIRAL VECTORS

8 GENE THERAPY MARKET, BY GENE TYPE

• 8.1 INTRODUCTION
• 8.2 DEFICIENCY
  • 8.2.1 TECHNOLOGICAL ADVANCEMENT IN GENE THERAPIES TO BOOST GROWTH
• 8.3 RECEPTOR
  • 8.3.1 INCREASING DEMAND FOR DEVELOPING RECEPTOR-BASED GENE THERAPY TO SUPPORT MARKET GROWTH
• 8.4 ANTIGEN
  • 8.4.1 INCREASING DEMAND FOR TARGETED THERAPIES TO PROPEL GROWTH
• 8.5 CYTOKINE
  • 8.5.1 RISING R&D TO SUPPORT MARKET GROWTH
• 8.6 TUMOR SUPPRESSOR
  • 8.6.1 RISING PREVALENCE OF CANCER TO PROPEL MARKET GROWTH
• 8.7 OTHER GENES

9 GENE THERAPY MARKET, BY THERAPEUTIC AREA

• 9.1 INTRODUCTION
• 9.2 NEUROLOGY
  • 9.2.1 ENHANCED DELIVERY METHODS AND ADVANCEMENTS IN GENE EDITING TECHNOLOGIES TO BOOST MARKET GROWTH
• 9.3 ONCOLOGY
  • 9.3.1 RISING BURDEN OF CANCER TO SUPPORT MARKET GROWTH
• 9.4 HEMATOLOGY
  • 9.4.1 INCREASING PREVALENCE OF GENETIC BLOOD DISORDERS TO BOOST MARKET GROWTH
• 9.5 OTHER THERAPEUTIC AREAS

10 GENE THERAPY MARKET, BY DELIVERY METHOD

• 10.1 INTRODUCTION
• 10.2 IN VIVO DELIVERY
  • 10.2.1 IN VIVO DELIVERY METHOD TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023
• 10.3 EX VIVO DELIVERY
  • 10.3.1 GROWING FOCUS ON ONCOLOGY THERAPEUTICS TO SUPPORT MARKET GROWTH

11 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION

• 11.1 INTRODUCTION
• 11.2 INTRAVENOUS ROUTE
  • 11.2.1 HIGH EFFECTIVENESS AND LARGE SHARE OF INTRAVENOUS PRODUCTS TO SUPPORT MARKET GROWTH
• 11.3 SUBCUTANEOUS ROUTE
  • 11.3.1 DEVELOPMENT OF IMPROVED DELIVERY DEVICES TO SUPPORT MARKET GROWTH
• 11.4 OTHER ROUTES

12 GENE THERAPY MARKET, BY END USER

• 12.1 INTRODUCTION
• 12.2 HOSPITALS
  • 12.2.1 GROWING DEMAND FOR ADVANCED THERAPIES TO BOOST MARKET
• 12.3 SPECIALTY CENTERS
  • 12.3.1 ADVANCEMENTS IN GENE THERAPY TECHNOLOGIES TO SUPPORT MARKET GROWTH
• 12.4 OTHER END USERS

13 GENE THERAPY MARKET, BY REGION

• 13.1 INTRODUCTION
• 13.2 NORTH AMERICA
  • 13.2.1 NORTH AMERICA: MACROECONOMIC ANALYSIS
  • 13.2.2 US
    • 13.2.2.1 US to dominate North American market during forecast period
  • 13.2.3 CANADA
    • 13.2.3.1 Government support for expanding manufacturing facilities to propel market growth
• 13.3 EUROPE
  • 13.3.1 EUROPE: MACROECONOMIC ANALYSIS
  • 13.3.2 GERMANY
    • 13.3.2.1 Growing pharmaceutical R&D and manufacturing to drive market
  • 13.3.3 UK
    • 13.3.3.1 Strong government support to propel market growth
  • 13.3.4 FRANCE
    • 13.3.4.1 Government investment in pharmaceutical industry to drive growth
  • 13.3.5 ITALY
    • 13.3.5.1 Initiatives for gene therapy development to drive growth
  • 13.3.6 SPAIN
    • 13.3.6.1 Expansion of biomanufacturing facilities to support market growth
  • 13.3.7 SWITZERLAND
    • 13.3.7.1 Presence of key pharmaceutical and biopharmaceutical companies to support market growth
  • 13.3.8 NETHERLANDS
    • 13.3.8.1 Growing awareness and strong focus on pharmaceutical R&D to support market growth
  • 13.3.9 REST OF EUROPE
• 13.4 ASIA PACIFIC
  • 13.4.1 ASIA PACIFIC: MACROECONOMIC ANALYSIS
  • 13.4.2 CHINA
    • 13.4.2.1 China to dominate Asia Pacific market during forecast period
  • 13.4.3 JAPAN
    • 13.4.3.1 Increasing initiatives supporting gene therapy adoption to propel market growth
  • 13.4.4 INDIA
    • 13.4.4.1 Favorable scenario for foreign direct investment to favor market growth
  • 13.4.5 AUSTRALIA
    • 13.4.5.1 Increasing demand for innovative therapies to propel market
  • 13.4.6 SOUTH KOREA
    • 13.4.6.1 Increased export of drugs to support market growth
  • 13.4.7 THAILAND
    • 13.4.7.1 Favorable government policies to propel adoption of advanced therapies
  • 13.4.8 REST OF ASIA PACIFIC
• 13.5 LATIN AMERICA
  • 13.5.1 LATIN AMERICA: MACROECONOMIC ANALYSIS
  • 13.5.2 BRAZIL
    • 13.5.2.1 Brazil to dominate LATAM market during forecast period
  • 13.5.3 MEXICO
    • 13.5.3.1 Rising demand for chronic disease treatment to support market growth
  • 13.5.4 REST OF LATIN AMERICA
• 13.6 MIDDLE EAST
  • 13.6.1 MIDDLE EAST: MACROECONOMIC ANALYSIS
  • 13.6.2 GCC COUNTRIES
    • 13.6.2.1 Saudi Arabia
      • 13.6.2.1.1 Growing healthcare expenditure to boost market growth
    • 13.6.2.2 UAE
      • 13.6.2.2.1 Growing focus on genetic medicine development projects to drive market
    • 13.6.2.3 Rest of GCC Countries
  • 13.6.3 REST OF MIDDLE EAST
• 13.7 AFRICA
  • 13.7.1 HIGH GROWTH POTENTIAL OF AFRICAN MARKETS TO ATTRACT KEY PLAYERS
  • 13.7.2 AFRICA: MACROECONOMIC ANALYSIS

14 COMPETITIVE LANDSCAPE

• 14.1 OVERVIEW
• 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022-2024
  • 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN GENE THERAPY MARKET, 2022-2024
• 14.3 REVENUE ANALYSIS, 2021-2023
• 14.4 MARKET SHARE ANALYSIS, 2023
• 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 14.5.1 STARS
  • 14.5.2 EMERGING LEADERS
  • 14.5.3 PERVASIVE PLAYERS
  • 14.5.4 PARTICIPANTS
  • 14.5.5 COMPETITIVE BENCHMARKING: KEY PLAYERS, 2023
    • 14.5.5.1 Company footprint
    • 14.5.5.2 Region footprint
    • 14.5.5.3 Therapy type footprint
    • 14.5.5.4 Therapeutic area footprint
    • 14.5.5.5 Route of administration footprint
• 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 14.6.1 PROGRESSIVE COMPANIES
  • 14.6.2 RESPONSIVE COMPANIES
  • 14.6.3 DYNAMIC COMPANIES
  • 14.6.4 STARTING BLOCKS
  • 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • 14.6.5.1 Detailed list of key startups/SMEs
    • 14.6.5.2 Competitive benchmarking of key startups/SMEs
• 14.7 VALUATION & FINANCIAL METRICS
  • 14.7.1 FINANCIAL METRICS
  • 14.7.2 COMPANY VALUATION
• 14.8 BRAND/PRODUCT COMPARISON
• 14.9 COMPETITIVE SCENARIO
  • 14.9.1 PRODUCT APPROVALS
  • 14.9.2 DEALS
  • 14.9.3 EXPANSIONS

15 COMPANY PROFILES

• 15.1 INTRODUCTION
• 15.2 KEY PLAYERS
  • 15.2.1 BIOGEN INC.
    • 15.2.1.1 Business overview
    • 15.2.1.2 Products offered
    • 15.2.1.3 Recent developments
      • 15.2.1.3.1 Deals
    • 15.2.1.4 MnM view
      • 15.2.1.4.1 Key strengths
      • 15.2.1.4.2 Strategic choices
      • 15.2.1.4.3 Weaknesses and competitive threats
  • 15.2.2 NOVARTIS AG
    • 15.2.2.1 Business overview
    • 15.2.2.2 Products offered
    • 15.2.2.3 Recent developments
      • 15.2.2.3.1 Deals
      • 15.2.2.3.2 Expansions
      • 15.2.2.3.3 Other developments
    • 15.2.2.4 MnM view
      • 15.2.2.4.1 Key strengths
      • 15.2.2.4.2 Strategic choices
      • 15.2.2.4.3 Weaknesses and competitive threats
  • 15.2.3 ALNYLAM PHARMACEUTICALS, INC.
    • 15.2.3.1 Business overview
    • 15.2.3.2 Products offered
    • 15.2.3.3 Recent developments
      • 15.2.3.3.1 Product approvals
      • 15.2.3.3.2 Deals
      • 15.2.3.3.3 Other developments
    • 15.2.3.4 MnM view
      • 15.2.3.4.1 Key strengths
      • 15.2.3.4.2 Strategic choices
      • 15.2.3.4.3 Weaknesses and competitive threats
  • 15.2.4 SAREPTA THERAPEUTICS, INC.
    • 15.2.4.1 Business overview
    • 15.2.4.2 Products offered
    • 15.2.4.3 Recent developments
      • 15.2.4.3.1 Product approvals
      • 15.2.4.3.2 Deals
    • 15.2.4.4 MnM view
      • 15.2.4.4.1 Key strengths
      • 15.2.4.4.2 Strategic choices
      • 15.2.4.4.3 Weaknesses and competitive threats
  • 15.2.5 JAZZ PHARMACEUTICALS PLC
    • 15.2.5.1 Business overview
    • 15.2.5.2 Products offered
    • 15.2.5.3 Recent developments
      • 15.2.5.3.1 Expansions
    • 15.2.5.4 MnM view
      • 15.2.5.4.1 Key strengths
      • 15.2.5.4.2 Strategic choices
      • 15.2.5.4.3 Weaknesses and competitive threats
  • 15.2.6 FERRING B.V.
    • 15.2.6.1 Business overview
    • 15.2.6.2 Products offered
    • 15.2.6.3 Recent developments
      • 15.2.6.3.1 Product approvals
      • 15.2.6.3.2 Deals
      • 15.2.6.3.3 Expansions
  • 15.2.7 PFIZER INC.
    • 15.2.7.1 Business overview
    • 15.2.7.2 Products offered
    • 15.2.7.3 Recent developments
      • 15.2.7.3.1 Product approvals
      • 15.2.7.3.2 Deals
  • 15.2.8 AMGEN, INC.
    • 15.2.8.1 Business overview
    • 15.2.8.2 Products offered
    • 15.2.8.3 Recent developments
      • 15.2.8.3.1 Deals
      • 15.2.8.3.2 Expansions
  • 15.2.9 JOHNSON & JOHNSON SERVICES, INC.
    • 15.2.9.1 Business overview
    • 15.2.9.2 Products offered
    • 15.2.9.3 Recent developments
      • 15.2.9.3.1 Deals
      • 15.2.9.3.2 Other developments
  • 15.2.10 DAIICHI SANKYO COMPANY, LIMITED.
    • 15.2.10.1 Business overview
    • 15.2.10.2 Products offered
  • 15.2.11 BIOMARIN PHARMACEUTICAL INC.
    • 15.2.11.1 Business overview
    • 15.2.11.2 Products offered
    • 15.2.11.3 Recent developments
      • 15.2.11.3.1 Product approvals
      • 15.2.11.3.2 Expansions
  • 15.2.12 KYOWA KIRIN CO., LTD.
    • 15.2.12.1 Business overview
    • 15.2.12.2 Products offered
    • 15.2.12.3 Recent developments
      • 15.2.12.3.1 Product approvals
      • 15.2.12.3.2 Deals
  • 15.2.13 NIPPON SHINYAKU CO., LTD.
    • 15.2.13.1 Business overview
    • 15.2.13.2 Products offered
    • 15.2.13.3 Recent developments
      • 15.2.13.3.1 Deals
  • 15.2.14 PTC THERAPEUTICS
    • 15.2.14.1 Business overview
    • 15.2.14.2 Products offered
    • 15.2.14.3 Recent developments
      • 15.2.14.3.1 Product approvals
  • 15.2.15 UNIQURE NV.
    • 15.2.15.1 Business overview
    • 15.2.15.2 Products offered
    • 15.2.15.3 Recent developments
      • 15.2.15.3.1 Deals
• 15.3 OTHER PLAYERS
  • 15.3.1 JUVENTAS CELL THERAPY LTD.
  • 15.3.2 CRISPR THERAPEUTICS
  • 15.3.3 BLUEBIRD BIO, INC.
  • 15.3.4 KRYSTAL BIOTECH, INC.
  • 15.3.5 SHANGHAI SUNWAY BIOTECH CO., LTD.
  • 15.3.6 JW (CAYMAN) THERAPEUTICS CO. LTD
  • 15.3.7 IASO BIOTECHNOLOGY
  • 15.3.8 CARSGEN THERAPEUTICS HOLDINGS LIMITED
  • 15.3.9 ADAPTIMMUNE
  • 15.3.10 SIBIONO GENETECH CO. LTD.
  • 15.3.11 ULTRAGENYX PHARMACEUTICAL INC.

16 APPENDIX

• 16.1 DISCUSSION GUIDE
• 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 16.3 CUSTOMIZATION OPTIONS
• 16.4 RELATED REPORTS
• 16.5 AUTHOR DETAILS

List of Tables

• TABLE 1 GENE THERAPY MARKET: INCLUSIONS & EXCLUSIONS
• TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
• TABLE 3 GENE THERAPY MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
• TABLE 4 GENE THERAPY MARKET: KEY PRODUCT APPROVALS, 2022-2024
• TABLE 5 GENE THERAPY MARKET: INVESTMENTS AND FINANCING BY STARTUPS, 2024
• TABLE 6 GENE THERAPY MARKET: LIST OF ADVANCED PLATFORMS LAUNCHED IN 2022-2024
• TABLE 7 NUMBER OF CLINICAL TRIALS FOR GENE THERAPY DRUGS, 2024
• TABLE 8 COST OF KEY GENE THERAPY PRODUCTS, 2024
• TABLE 9 GENE THERAPY MARKET: RAW MATERIAL VENDORS
• TABLE 10 GENE THERAPY MARKET: PRODUCT VENDORS
• TABLE 11 GENE THERAPY MARKET: ROLE OF END USERS
• TABLE 12 GENE THERAPY MARKET: REGULATORY BODIES
• TABLE 13 GENE THERAPY MARKET: INDICATIVE LIST OF PATENTS, 2023-2024
• TABLE 14 GENE THERAPY PRODUCTS IN CLINICAL PIPELINE
• TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 18 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 19 COUNTRY-WISE REGULATORY SCENARIO FOR GENE THERAPY PRODUCTS
• TABLE 20 US: REIMBURSEMENT CODES FOR GENE THERAPY PRODUCTS
• TABLE 21 EUROPE: REIMBURSEMENT SCENARIO FOR GENE THERAPY PRODUCTS, BY COUNTRY
• TABLE 22 AVERAGE SELLING PRICE TREND OF GENE THERAPIES, BY KEY PLAYER, 2022-2024 (USD)
• TABLE 23 AVERAGE SELLING PRICE TREND OF GENE THERAPIES, BY REGION, 2022-2024 (USD)
• TABLE 24 GENE THERAPY MARKET: KEY CONFERENCES & EVENTS, 2025-2026
• TABLE 25 GENE THERAPY MARKET: IMPACT OF PORTER'S FIVE FORCES
• TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%)
• TABLE 27 KEY BUYING CRITERIA FOR GENE THERAPY PRODUCTS, BY END USER
• TABLE 28 GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 29 GENE SILENCING THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 30 NORTH AMERICA: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 31 EUROPE: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 32 ASIA PACIFIC: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 33 LATIN AMERICA: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 34 MIDDLE EAST: GENE SILENCING THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 35 GCC COUNTRIES: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 36 CELL REPLACEMENT THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 37 NORTH AMERICA: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 38 EUROPE: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 39 ASIA PACIFIC: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 40 LATIN AMERICA: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 41 MIDDLE EAST: CELL REPLACEMENT THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 42 GCC COUNTRIES: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 43 GENE AUGMENTATION THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 44 NORTH AMERICA: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 45 EUROPE: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 46 ASIA PACIFIC: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 47 LATIN AMERICA: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 48 MIDDLE EAST: GENE AUGMENTATION THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 49 GCC COUNTRIES: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 50 OTHER GENE THERAPIES MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 51 NORTH AMERICA: OTHER GENE THERAPIES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 52 EUROPE: OTHER GENE THERAPIES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 53 ASIA PACIFIC: OTHER GENE THERAPIES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 54 LATIN AMERICA: OTHER GENE THERAPIES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 55 MIDDLE EAST: OTHER GENE THERAPIES MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 56 GCC COUNTRIES: OTHER GENE THERAPIES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 57 GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 58 VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 59 VIRAL VECTOR-BASED GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 60 NORTH AMERICA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 61 EUROPE: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 62 ASIA PACIFIC: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 63 LATIN AMERICA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 64 MIDDLE EAST: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 65 GCC COUNTRIES: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 66 RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 67 RETROVIRAL VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 68 NORTH AMERICA: RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 69 EUROPE: RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 70 ASIA PACIFIC: RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 71 LATIN AMERICA: RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 72 MIDDLE EAST: RETROVIRAL VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 73 GCC COUNTRIES: RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 74 GAMMA RETROVIRAL VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 75 NORTH AMERICA: GAMMA RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 76 EUROPE: GAMMA RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 77 ASIA PACIFIC: GAMMA RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 78 LATIN AMERICA: GAMMA RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 79 MIDDLE EAST: GAMMA RETROVIRAL VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 80 GCC COUNTRIES: GAMMA RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 81 LENTIVIRAL VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 82 NORTH AMERICA: LENTIVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 83 EUROPE: LENTIVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 84 ASIA PACIFIC: LENTIVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 85 LATIN AMERICA: LENTIVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 86 MIDDLE EAST: LENTIVIRAL VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 87 GCC COUNTRIES: LENTIVIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 88 AAV VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 89 NORTH AMERICA: AAV VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 90 EUROPE: AAV VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 91 ASIA PACIFIC: AAV VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 92 LATIN AMERICA: AAV VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 93 MIDDLE EAST: AAV VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 94 GCC COUNTRIES: AAV VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 95 OTHER VIRAL VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 96 NORTH AMERICA: OTHER VIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 97 EUROPE: OTHER VIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 98 ASIA PACIFIC: OTHER VIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 99 LATIN AMERICA: OTHER VIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 100 MIDDLE EAST: OTHER VIRAL VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 101 GCC COUNTRIES: OTHER VIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 102 NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 103 NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 104 NORTH AMERICA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 105 EUROPE: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 106 ASIA PACIFIC: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 107 LATIN AMERICA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 108 MIDDLE EAST: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 109 GCC COUNTRIES: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 110 OLIGONUCLEOTIDE VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 111 NORTH AMERICA: OLIGONUCLEOTIDE VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 112 EUROPE: OLIGONUCLEOTIDE VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 113 ASIA PACIFIC: OLIGONUCLEOTIDE VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 114 LATIN AMERICA: OLIGONUCLEOTIDE VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 115 MIDDLE EAST: OLIGONUCLEOTIDE VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 116 GCC COUNTRIES: OLIGONUCLEOTIDE VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 117 OTHER NON-VIRAL VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 118 NORTH AMERICA: OTHER NON-VIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 119 EUROPE: OTHER NON-VIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 120 ASIA PACIFIC: OTHER NON-VIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 121 LATIN AMERICA: OTHER NON-VIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 122 MIDDLE EAST: OTHER NON-VIRAL VECTORS MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 123 GCC COUNTRIES: OTHER NON-VIRAL VECTORS MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 124 GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 125 DEFICIENCY GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 126 NORTH AMERICA: DEFICIENCY GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 127 EUROPE: DEFICIENCY GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 128 ASIA PACIFIC: DEFICIENCY GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 129 LATIN AMERICA: GENE THERAPY MARKET FOR DEFICIENCY GENES, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 130 MIDDLE EAST: GENE THERAPY MARKET FOR DEFICIENCY GENES, BY REGION, 2022-2032 (USD MILLION)
• TABLE 131 GCC COUNTRIES: GENE THERAPY MARKET FOR DEFICIENCY GENES, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 132 RECEPTOR GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 133 NORTH AMERICA: RECEPTOR GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 134 EUROPE: RECEPTOR GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 135 ASIA PACIFIC: RECEPTOR GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 136 LATIN AMERICA: RECEPTOR GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 137 MIDDLE EAST: RECEPTOR GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 138 GCC COUNTRIES: RECEPTOR GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 139 ANTIGEN GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 140 NORTH AMERICA: ANTIGEN GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 141 EUROPE: ANTIGEN GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 142 ASIA PACIFIC: ANTIGEN GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 143 LATIN AMERICA: ANTIGEN GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 144 MIDDLE EAST: ANTIGEN GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 145 GCC COUNTRIES: ANTIGEN GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 146 CYTOKINE GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 147 NORTH AMERICA: CYTOKINE GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 148 EUROPE: CYTOKINE GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 149 ASIA PACIFIC: CYTOKINE GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 150 LATIN AMERICA: CYTOKINE GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 151 MIDDLE EAST: CYTOKINE GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 152 GCC COUNTRIES: CYTOKINE GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 153 TUMOR SUPPRESSOR GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 154 NORTH AMERICA: TUMOR SUPPRESSOR GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 155 EUROPE: TUMOR SUPPRESSOR GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 156 ASIA PACIFIC: TUMOR SUPPRESSOR GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 157 LATIN AMERICA: TUMOR SUPPRESSOR GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 158 MIDDLE EAST: TUMOR SUPPRESSOR GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 159 GCC COUNTRIES: TUMOR SUPPRESSOR GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 160 GENE THERAPY MARKET FOR OTHER GENES, BY REGION, 2022-2032 (USD MILLION)
• TABLE 161 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER GENES, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 162 EUROPE: GENE THERAPY MARKET FOR OTHER GENES, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 163 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER GENES, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 164 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER GENES, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 165 MIDDLE EAST: GENE THERAPY MARKET FOR OTHER GENES, BY REGION, 2022-2032 (USD MILLION)
• TABLE 166 GCC COUNTRIES: GENE THERAPY MARKET FOR OTHER GENES, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 167 GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 168 GENE THERAPY MARKET FOR NEUROLOGY, BY REGION, 2022-2032 (USD MILLION)
• TABLE 169 NORTH AMERICA: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 170 EUROPE: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 171 ASIA PACIFIC: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 172 LATIN AMERICA: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 173 MIDDLE EAST: GENE THERAPY MARKET FOR NEUROLOGY, BY REGION, 2022-2032 (USD MILLION)
• TABLE 174 GCC COUNTRIES: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 175 GENE THERAPY MARKET FOR ONCOLOGY, BY REGION, 2022-2032 (USD MILLION)
• TABLE 176 NORTH AMERICA: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 177 EUROPE: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 178 ASIA PACIFIC: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 179 LATIN AMERICA: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 180 MIDDLE EAST: GENE THERAPY MARKET FOR ONCOLOGY, BY REGION, 2022-2032 (USD MILLION)
• TABLE 181 GCC COUNTRIES: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 182 GENE THERAPY MARKET FOR HEMATOLOGY, BY REGION, 2022-2032 (USD MILLION)
• TABLE 183 NORTH AMERICA: GENE THERAPY MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 184 EUROPE: GENE THERAPY MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 185 ASIA PACIFIC: GENE THERAPY MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 186 LATIN AMERICA: GENE THERAPY MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 187 MIDDLE EAST: GENE THERAPY MARKET FOR HEMATOLOGY, BY REGION, 2022-2032 (USD MILLION)
• TABLE 188 GCC COUNTRIES: GENE THERAPY MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 189 GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022-2032 (USD MILLION)
• TABLE 190 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 191 EUROPE: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 192 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 193 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 194 MIDDLE EAST: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022-2032 (USD MILLION)
• TABLE 195 GCC COUNTRIES: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 196 GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 197 IN VIVO GENE THERAPY: COMMERCIALIZED AND PIPELINE PRODUCTS
• TABLE 198 IN VIVO GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 199 NORTH AMERICA: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 200 EUROPE: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 201 ASIA PACIFIC: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 202 LATIN AMERICA: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 203 MIDDLE EAST: IN VIVO GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 204 GCC COUNTRIES: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 205 EX VIVO GENE THERAPY: COMMERCIALIZED AND PIPELINE PRODUCTS
• TABLE 206 EX VIVO GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 207 NORTH AMERICA: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 208 EUROPE: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 209 APAC: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 210 LATIN AMERICA: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 211 MIDDLE EAST: EX VIVO GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 212 GCC COUNTRIES: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 213 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 214 EXAMPLES OF INTRAVENOUSLY DELIVERED GENE THERAPY
• TABLE 215 INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 216 NORTH AMERICA: INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 217 EUROPE: INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 218 ASIA PACIFIC: INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 219 LATIN AMERICA: INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 220 MIDDLE EAST: INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 221 GCC COUNTRIES: INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 222 SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 223 NORTH AMERICA: SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 224 EUROPE: SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 225 ASIA PACIFIC: SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 226 LATIN AMERICA: SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 227 MIDDLE EAST: SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 228 GCC COUNTRIES: SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 229 EXAMPLE OF GENE THERAPIES ADMINISTERED THROUGH OTHER ROUTES
• TABLE 230 GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022-2032 (USD MILLION)
• TABLE 231 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 232 EUROPE: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 233 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 234 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 235 MIDDLE EAST: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022-2032 (USD MILLION)
• TABLE 236 GCC COUNTRIES: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 237 GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 238 GENE THERAPY MARKET FOR HOSPITALS, BY REGION, 2022-2032 (USD MILLION)
• TABLE 239 NORTH AMERICA: GENE THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 240 EUROPE: GENE THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 241 ASIA PACIFIC: GENE THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 242 LATIN AMERICA: GENE THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 243 MIDDLE EAST: GENE THERAPY MARKET FOR HOSPITALS, BY REGION, 2022-2032 (USD MILLION)
• TABLE 244 GCC COUNTRIES: GENE THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 245 GENE THERAPY MARKET FOR SPECIALTY CENTERS, BY REGION, 2022-2032 (USD MILLION)
• TABLE 246 NORTH AMERICA: GENE THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 247 EUROPE: GENE THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 248 ASIA PACIFIC: GENE THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 249 LATIN AMERICA: GENE THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 250 MIDDLE EAST: GENE THERAPY MARKET FOR SPECIALTY CENTERS, BY REGION, 2022-2032 (USD MILLION)
• TABLE 251 GCC COUNTRIES: GENE THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 252 GENE THERAPY MARKET FOR OTHER END USERS, BY REGION, 2022-2032 (USD MILLION)
• TABLE 253 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 254 EUROPE: GENE THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 255 ASIA PACIFIC GENE THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 256 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 257 MIDDLE EAST: GENE THERAPY MARKET FOR OTHER END USERS, BY REGION, 2022-2032 (USD MILLION)
• TABLE 258 GCC COUNTRIES: GENE THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 259 GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 260 NORTH AMERICA: MACROECONOMIC OUTLOOK FOR GENE THERAPY MARKET
• TABLE 261 NORTH AMERICA: GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 262 NORTH AMERICA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 263 NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 264 NORTH AMERICA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 265 NORTH AMERICA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 266 NORTH AMERICA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 267 NORTH AMERICA: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 268 NORTH AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 269 NORTH AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 270 NORTH AMERICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 271 NORTH AMERICA: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 272 US FDA APPROVALS FOR GENE THERAPY PRODUCTS, 2022-2024
• TABLE 273 US: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 274 US: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 275 US: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 276 US: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 277 US: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 278 US: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 279 US: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 280 US: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 281 US: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 282 US: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 283 CANADA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 284 CANADA: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 285 CANADA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 286 CANADA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 287 CANADA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 288 CANADA: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 289 CANADA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 290 CANADA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 291 CANADA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 292 CANADA: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 293 EUROPE: MACROECONOMIC OUTLOOK FOR GENE THERAPY MARKET
• TABLE 294 EUROPE: GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 295 EUROPE: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 296 EUROPE: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 297 EUROPE: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 298 EUROPE: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 299 EUROPE: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 300 EUROPE: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 301 EUROPE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 302 EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 303 EUROPE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 304 EUROPE: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 305 GERMANY: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 306 GERMANY: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 307 GERMANY: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 308 GERMANY: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 309 GERMANY: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 310 GERMANY: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 311 GERMANY: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 312 GERMANY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 313 GERMANY: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 314 GERMANY: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 315 UK: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 316 UK: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 317 UK: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 318 UK: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 319 UK: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 320 UK: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 321 UK: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 322 UK: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 323 UK: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 324 UK: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 325 FRANCE: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 326 FRANCE: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 327 FRANCE: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 328 FRANCE: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 329 FRANCE: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 330 FRANCE: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 331 FRANCE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 332 FRANCE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 333 FRANCE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 334 FRANCE: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 335 ITALY: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 336 ITALY: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 337 ITALY: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 338 ITALY: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 339 ITALY: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 340 ITALY: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 341 ITALY: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 342 ITALY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 343 ITALY: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 344 ITALY: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 345 SPAIN: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 346 SPAIN: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 347 SPAIN: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 348 SPAIN: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 349 SPAIN: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 350 SPAIN: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 351 SPAIN: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 352 SPAIN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 353 SPAIN: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 354 SPAIN: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 355 SWITZERLAND: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 356 SWITZERLAND: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 357 SWITZERLAND: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 358 SWITZERLAND: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 359 SWITZERLAND: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 360 SWITZERLAND: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 361 SWITZERLAND: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 362 SWITZERLAND: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 363 SWITZERLAND: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 364 SWITZERLAND: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 365 NETHERLANDS: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 366 NETHERLANDS: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 367 NETHERLANDS: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 368 NETHERLANDS: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 369 NETHERLANDS: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 370 NETHERLANDS: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 371 NETHERLANDS: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 372 NETHERLANDS: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 373 NETHERLANDS: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 374 NETHERLANDS: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 375 REST OF EUROPE: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 376 REST OF EUROPE: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 377 REST OF EUROPE: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 378 REST OF EUROPE: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 379 REST OF EUROPE: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 380 REST OF EUROPE: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 381 REST OF EUROPE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 382 REST OF EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 383 REST OF EUROPE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 384 REST OF EUROPE: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 385 ASIA PACIFIC: MACROECONOMIC OUTLOOK FOR GENE THERAPY MARKET
• TABLE 386 ASIA PACIFIC: GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 387 ASIA PACIFIC: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 388 ASIA PACIFIC: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 389 ASIA PACIFIC: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 390 ASIA PACIFIC: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 391 ASIA PACIFIC: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 392 ASIA PACIFIC: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 393 ASIA PACIFIC: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 394 ASIA PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 395 ASIA PACIFIC: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 396 ASIA PACIFIC: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 397 CHINA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 398 CHINA: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 399 CHINA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 400 CHINA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 401 CHINA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 402 CHINA: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 403 CHINA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 404 CHINA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 405 CHINA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 406 CHINA: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 407 JAPAN: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 408 JAPAN: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 409 JAPAN: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 410 JAPAN: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 411 JAPAN: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 412 JAPAN: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 413 JAPAN: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 414 JAPAN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 415 JAPAN: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 416 JAPAN: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 417 INDIA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 418 INDIA: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 419 INDIA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 420 INDIA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 421 INDIA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 422 INDIA: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 423 INDIA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 424 INDIA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 425 INDIA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 426 INDIA: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 427 AUSTRALIA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 428 AUSTRALIA: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 429 AUSTRALIA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 430 AUSTRALIA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 431 AUSTRALIA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 432 AUSTRALIA: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 433 AUSTRALIA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 434 AUSTRALIA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 435 AUSTRALIA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 436 AUSTRALIA: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 437 SOUTH KOREA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 438 SOUTH KOREA: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 439 SOUTH KOREA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 440 SOUTH KOREA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 441 SOUTH KOREA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 442 SOUTH KOREA: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 443 SOUTH KOREA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 444 SOUTH KOREA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 445 SOUTH KOREA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 446 SOUTH KOREA: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 447 THAILAND: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 448 THAILAND: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 449 THAILAND: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 450 THAILAND: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 451 THAILAND: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 452 THAILAND: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 453 THAILAND: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 454 THAILAND: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 455 THAILAND: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 456 THAILAND: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 457 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 458 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 459 REST OF ASIA PACIFIC: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 460 REST OF ASIA PACIFIC: RETROVIRAL VECTORS MARKET, BY TYPE 2022-2032 (USD MILLION)
• TABLE 461 REST OF ASIA PACIFIC: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 462 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 463 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 464 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 465 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 466 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 467 LATIN AMERICA: MACROECONOMIC OUTLOOK FOR GENE THERAPY MARKET
• TABLE 468 LATIN AMERICA: GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 469 LATIN AMERICA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 470 LATIN AMERICA: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 471 LATIN AMERICA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 472 LATIN AMERICA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 473 LATIN AMERICA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 474 LATIN AMERICA: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 475 LATIN AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 476 LATIN AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 477 LATIN AMERICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 478 LATIN AMERICA: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 479 BRAZIL: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 480 BRAZIL: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 481 BRAZIL: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 482 BRAZIL: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 483 BRAZIL: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 484 BRAZIL: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 485 BRAZIL: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 486 BRAZIL: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 487 BRAZIL: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 488 BRAZIL: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 489 MEXICO: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 490 MEXICO: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 491 MEXICO: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 492 MEXICO: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 493 MEXICO: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 494 MEXICO: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 495 MEXICO: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 496 MEXICO: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 497 MEXICO: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 498 MEXICO: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 499 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 500 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 501 REST OF LATIN AMERICA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 502 REST OF LATIN AMERICA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 503 REST OF LATIN AMERICA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 504 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 505 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 506 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 507 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 508 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 509 MIDDLE EAST: MACROECONOMIC OUTLOOK FOR GENE THERAPY MARKET
• TABLE 510 MIDDLE EAST: GENE THERAPY MARKET, BY REGION, 2022-2032 (USD MILLION)
• TABLE 511 MIDDLE EAST: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 512 MIDDLE EAST: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 513 MIDDLE EAST: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 514 MIDDLE EAST: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 515 MIDDLE EAST: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 516 MIDDLE EAST: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 517 MIDDLE EAST: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 518 MIDDLE EAST: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 519 MIDDLE EAST: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 520 MIDDLE EAST: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 521 GCC COUNTRIES: GENE THERAPY MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
• TABLE 522 GCC COUNTRIES: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 523 GCC COUNTRIES: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 524 GCC COUNTRIES: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 525 GCC COUNTRIES: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 526 GCC COUNTRIES: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 527 GCC COUNTRIES: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 528 GCC COUNTRIES: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 529 GCC COUNTRIES: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 530 GCC COUNTRIES: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 531 GCC COUNTRIES: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 532 SAUDI ARABIA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 533 SAUDI ARABIA: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 534 SAUDI ARABIA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 535 SAUDI ARABIA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 536 SAUDI ARABIA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 537 SAUDI ARABIA: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 538 SAUDI ARABIA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 539 SAUDI ARABIA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 540 SAUDI ARABIA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 541 SAUDI ARABIA: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 542 UAE: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 543 UAE: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 544 UAE: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 545 UAE: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 546 UAE: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 547 UAE: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 548 UAE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 549 UAE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 550 UAE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 551 UAE: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 552 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 553 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 554 REST OF GCC COUNTRIES: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 555 REST OF GCC COUNTRIES: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 556 REST OF GCC COUNTRIES: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 557 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 558 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 559 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 560 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 561 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 562 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 563 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 564 REST OF MIDDLE EAST: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 565 REST OF MIDDLE EAST: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 566 REST OF MIDDLE EAST: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 567 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 568 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 569 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 570 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 571 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 572 AFRICA: MACROECONOMIC OUTLOOK FOR GENE THERAPY MARKET
• TABLE 573 AFRICA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022-2032 (USD MILLION)
• TABLE 574 AFRICA: GENE THERAPY MARKET, BY VECTOR, 2022-2032 (USD MILLION)
• TABLE 575 AFRICA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 576 AFRICA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 577 AFRICA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022-2032 (USD MILLION)
• TABLE 578 AFRICA: GENE THERAPY MARKET, BY GENE TYPE, 2022-2032 (USD MILLION)
• TABLE 579 AFRICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022-2032 (USD MILLION)
• TABLE 580 AFRICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022-2032 (USD MILLION)
• TABLE 581 AFRICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
• TABLE 582 AFRICA: GENE THERAPY MARKET, BY END USER, 2022-2032 (USD MILLION)
• TABLE 583 STRATEGIES DEPLOYED BY KEY COMPANIES IN GENE THERAPY MARKET
• TABLE 584 GENE THERAPY MARKET: DEGREE OF COMPETITION
• TABLE 585 GENE THERAPY MARKET: REGION FOOTPRINT
• TABLE 586 GENE THERAPY MARKET: THERAPY TYPE FOOTPRINT
• TABLE 587 GENE THERAPY MARKET: THERAPEUTIC AREA FOOTPRINT
• TABLE 588 GENE THERAPY MARKET: ROUTE OF ADMINISTRATION FOOTPRINT
• TABLE 589 GENE THERAPY MARKET: DETAILED LIST OF KEY STARTUPS/SMES
• TABLE 590 GENE THERAPY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
• TABLE 591 GENE THERAPY MARKET: PRODUCT APPROVALS, JANUARY 2022-DECEMBER 2024
• TABLE 592 GENE THERAPY MARKET: DEALS, JANUARY 2022-DECEMBER 2024
• TABLE 593 GENE THERAPY MARKET: EXPANSIONS, JANUARY 2022-DECEMBER 2024
• TABLE 594 BIOGEN: COMPANY OVERVIEW
• TABLE 595 BIOGEN: PRODUCTS OFFERED
• TABLE 596 BIOGEN: DEALS, JANUARY 2022-DECEMBER 2024
• TABLE 597 NOVARTIS: COMPANY OVERVIEW
• TABLE 598 NOVARTIS: PRODUCTS OFFERED
• TABLE 599 NOVARTIS: DEALS, JANUARY 2022-DECEMBER 2024
• TABLE 600 NOVARTIS: EXPANSIONS, JANUARY 2022-DECEMBER 2024
• TABLE 601 NOVARTIS: OTHER DEVELOPMENTS, JANUARY 2022-DECEMBER 2024
• TABLE 602 ALNYLAM PHARMACEUTICALS: COMPANY OVERVIEW
• TABLE 603 ALNYLAM PHARMACEUTICALS: PRODUCTS OFFERED
• TABLE 604 ALNYLAM PHARMACEUTICALS: PRODUCT APPROVALS, JANUARY 2022-DECEMBER 2024
• TABLE 605 ALNYLAM PHARMACEUTICALS: DEALS, JANUARY 2022-DECEMBER 2024
• TABLE 606 ALNYLAM PHARMACEUTICALS: OTHER DEVELOPMENTS, JANUARY 2022-DECEMBER 2024
• TABLE 607 SAREPTA THERAPEUTICS: COMPANY OVERVIEW
• TABLE 608 SAREPTA THERAPEUTICS: PRODUCTS OFFERED
• TABLE 609 SAREPTA THERAPEUTICS: PRODUCT APPROVALS, JANUARY 2022-DECEMBER 2024
• TABLE 610 SAREPTA THERAPEUTICS: DEALS, JANUARY 2022-DECEMBER 2024
• TABLE 611 JAZZ PHARMACEUTICALS: COMPANY OVERVIEW
• TABLE 612 JAZZ PHARMACEUTICALS: PRODUCTS OFFERED
• TABLE 613 JAZZ PHARMACEUTICALS: EXPANSIONS, JANUARY 2022-DECEMBER 2024
• TABLE 614 FERRING: COMPANY OVERVIEW
• TABLE 615 FERRING: PRODUCTS OFFERED
• TABLE 616 FERRING: PRODUCT APPROVALS, JANUARY 2022-DECEMBER 2024
• TABLE 617 FERRING: DEALS, JANUARY 2022-DECEMBER 2024
• TABLE 618 FERRING: EXPANSIONS, JANUARY 2022-DECEMBER 2024
• TABLE 619 PFIZER: COMPANY OVERVIEW
• TABLE 620 PFIZER: PRODUCTS OFFERED
• TABLE 621 PFIZER: PRODUCT APPROVALS, JANUARY 2022-DECEMBER 2024
• TABLE 622 PFIZER: DEALS, JANUARY 2022-DECEMBER 2024
• TABLE 623 AMGEN: COMPANY OVERVIEW
• TABLE 624 AMGEN: PRODUCTS OFFERED
• TABLE 625 AMGEN: DEALS, JANUARY 2022-DECEMBER 2024
• TABLE 626 AMGEN: EXPANSIONS, JANUARY 2022-DECEMBER 2024
• TABLE 627 JOHNSON & JOHNSON SERVICES: COMPANY OVERVIEW
• TABLE 628 JOHNSON & JOHNSON SERVICES: PRODUCTS OFFERED
• TABLE 629 JOHNSON & JOHNSON SERVICES: DEALS, JANUARY 2022-DECEMBER 2024
• TABLE 630 JOHNSON & JOHNSON SERVICES: OTHER DEVELOPMENTS, JANUARY 2022-DECEMBER 2024
• TABLE 631 DAIICHI SANKYO COMPANY: COMPANY OVERVIEW
• TABLE 632 DAIICHI SANKYO COMPANY: PRODUCTS OFFERED
• TABLE 633 BIOMARIN PHARMACEUTICAL: COMPANY OVERVIEW
• TABLE 634 BIOMARIN PHARMACEUTICAL: PRODUCTS OFFERED
• TABLE 635 BIOMARIN PHARMACEUTICAL: PRODUCT APPROVALS, JANUARY 2022-DECEMBER 2024
• TABLE 636 BIOMARIN PHARMACEUTICAL: EXPANSIONS, JANUARY 2022-DECEMBER 2024
• TABLE 637 KYOWA KIRIN: COMPANY OVERVIEW
• TABLE 638 KYOWA KIRIN: PRODUCTS OFFERED
• TABLE 639 KYOWA KIRIN: PRODUCT APPROVALS, JANUARY 2022-DECEMBER 2024
• TABLE 640 KYOWA KIRIN: DEALS, JANUARY 2022-DECEMBER 2024
• TABLE 641 NIPPON SHINYAKU: COMPANY OVERVIEW
• TABLE 642 NIPPON SHINYAKU: PRODUCTS OFFERED
• TABLE 643 NIPPON SHINYAKU: DEALS, JANUARY 2022-DECEMBER 2024
• TABLE 644 PTC THERAPEUTICS: COMPANY OVERVIEW
• TABLE 645 PTC THERAPEUTICS: PRODUCTS OFFERED
• TABLE 646 PTC THERAPEUTICS: PRODUCT APPROVALS, JANUARY 2022-DECEMBER 2024
• TABLE 647 UNIQURE: COMPANY OVERVIEW
• TABLE 648 UNIQURE: PRODUCTS OFFERED
• TABLE 649 UNIQURE: DEALS, JANUARY 2022-DECEMBER 2024
• TABLE 650 JUVENTAS CELL THERAPY: COMPANY OVERVIEW
• TABLE 651 CRISPR THERAPEUTICS: COMPANY OVERVIEW
• TABLE 652 BLUEBIRD BIO: COMPANY OVERVIEW
• TABLE 653 KRYSTAL BIOTECH: COMPANY OVERVIEW
• TABLE 654 SHANGHAI SUNWAY BIOTECH: COMPANY OVERVIEW
• TABLE 655 JW (CAYMAN) THERAPEUTICS: COMPANY OVERVIEW
• TABLE 656 IASO BIOTECHNOLOGY: COMPANY OVERVIEW
• TABLE 657 CARSGEN THERAPEUTICS HOLDINGS LIMITED: COMPANY OVERVIEW
• TABLE 658 ADAPTIMMUNE: COMPANY OVERVIEW
• TABLE 659 SIBIONO GENETECH CO. LTD.: COMPANY OVERVIEW
• TABLE 660 ULTRAGENYX PHARMACEUTICAL INC.: COMPANY OVERVIEW

List of Figures

• FIGURE 1 GENE THERAPY MARKET SEGMENTATION & REGIONAL SCOPE
• FIGURE 2 GENE THERAPY MARKET: YEARS CONSIDERED
• FIGURE 3 RESEARCH DESIGN
• FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: GENE THERAPY MARKET
• FIGURE 5 GENE THERAPY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
• FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
• FIGURE 7 ILLUSTRATIVE EXAMPLE OF NOVARTIS AG: REVENUE SHARE ANALYSIS (2023)
• FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
• FIGURE 9 GENE THERAPY MARKET: CAGR PROJECTIONS
• FIGURE 10 DATA TRIANGULATION METHODOLOGY
• FIGURE 11 GENE THERAPY MARKET, BY THERAPY TYPE, 2024 VS. 2032 (USD MILLION)
• FIGURE 12 GENE THERAPY MARKET, BY VECTOR, 2024 VS. 2032 (USD MILLION)
• FIGURE 13 GENE THERAPY MARKET, BY GENE TYPE, 2024 VS. 2032 (USD MILLION)
• FIGURE 14 GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2024 VS. 2032 (USD MILLION)
• FIGURE 15 GENE THERAPY MARKET, BY DELIVERY METHOD, 2024 VS. 2032 (USD MILLION)
• FIGURE 16 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2024
• FIGURE 17 GENE THERAPY MARKET, BY END USER, 2024 VS. 2032 (USD MILLION)
• FIGURE 18 GEOGRAPHICAL SNAPSHOT OF GENE THERAPY MARKET
• FIGURE 19 INCREASING INVESTMENTS IN GENE THERAPY RESEARCH-A KEY FACTOR DRIVING GROWTH
• FIGURE 20 GENE SILENCING THERAPY ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2024
• FIGURE 21 HOSPITALS TO DOMINATE END-USER MARKET TILL 2032
• FIGURE 22 GERMANY TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
• FIGURE 23 GENE THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 24 GENE THERAPY MARKET: VALUE CHAIN ANALYSIS
• FIGURE 25 GENE THERAPY MARKET: SUPPLY CHAIN ANALYSIS
• FIGURE 26 GENE THERAPY MARKET: ECOSYSTEM
• FIGURE 27 PATENT ANALYSIS FOR GENE THERAPY MARKET, JANUARY 2014-DECEMBER 2024
• FIGURE 28 AVERAGE SELLING PRICE TREND OF GENE THERAPIES, BY TYPE, 2022-2024 (USD)
• FIGURE 29 AVERAGE SELLING PRICE OF GENE THERAPIES, BY REGION, 2023 (USD)
• FIGURE 30 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• FIGURE 31 GENE THERAPY MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF GENE THERAPY PRODUCTS, BY DELIVERY METHOD
• FIGURE 33 KEY BUYING CRITERIA FOR GENE THERAPY PRODUCTS, BY END USER
• FIGURE 34 GENE THERAPY MARKET: INVESTMENT & FUNDING SCENARIO
• FIGURE 35 NORTH AMERICA: GENE THERAPY MARKET SNAPSHOT
• FIGURE 36 NIH FUNDING, 2014-2024
• FIGURE 37 EUROPE: GENE THERAPY MARKET SNAPSHOT
• FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS, 2021-2023 (USD MILLION)
• FIGURE 39 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
• FIGURE 40 GENE THERAPY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
• FIGURE 41 GENE THERAPY MARKET: COMPANY FOOTPRINT
• FIGURE 42 GENE THERAPY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
• FIGURE 43 EV/EBITDA OF KEY VENDORS
• FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
• FIGURE 45 GENE THERAPY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
• FIGURE 46 BIOGEN: COMPANY SNAPSHOT (2023)
• FIGURE 47 NOVARTIS: COMPANY SNAPSHOT (2023)
• FIGURE 48 ALNYLAM PHARMACEUTICALS: COMPANY SNAPSHOT (2023)
• FIGURE 49 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2023)
• FIGURE 50 JAZZ PHARMACEUTICALS: COMPANY SNAPSHOT (2023)
• FIGURE 51 FERRING: COMPANY SNAPSHOT (2023)
• FIGURE 52 PFIZER: COMPANY SNAPSHOT (2023)
• FIGURE 53 AMGEN: COMPANY SNAPSHOT (2023)
• FIGURE 54 JOHNSON & JOHNSON SERVICES: COMPANY SNAPSHOT (2023)
• FIGURE 55 DAIICHI SANKYO COMPANY: COMPANY SNAPSHOT (2023)
• FIGURE 56 BIOMARIN PHARMACEUTICAL: COMPANY SNAPSHOT (2023)
• FIGURE 57 KYOWA KIRIN: COMPANY SNAPSHOT (2023)
• FIGURE 58 NIPPON SHINYAKU: COMPANY SNAPSHOT (2023)
• FIGURE 59 PTC THERAPEUTICS: COMPANY SNAPSHOT (2023)
• FIGURE 60 UNIQURE: COMPANY SNAPSHOT (2023)